SAN FRANCISCO: Distinguishing between psychiatric disorders and AD is crucial because of the differing prognosis and management of the two.
This is the first study to examine the role of CSF biomarkers in the diagnosis of patients with cognitive symptoms and psychiatric disorders in routine daily clinical practice.
The use of cerebrospinal fluid (CSF) biomarkers in the early detection of Alzheimer disease (AD) has grown as the diagnostic criteria for AD have evolved over the past few years. The International Working Group for New Research Criteria for the Diagnosis of AD mandates the use of beta-amyloid (Aβ) and tau biomarkers via neuroimaging and CSF testing, and the National Institute on Aging–Alzheimer’s Association takes a similar stance in its criteria. Both sets of criteria recognize the concept of a preclinical stage AD that may be recognized before the onset of dementia and underscore the need for biomarkers to aid in early AD diagnosis…..